Abstract
Guideline on the use of iodinated contrast media in patients with kidney disease 2018
Highlights
Diagnostic imaging using iodinated contrast media is an essential procedure in the clinical setting and provides a large amount of beneficial information
Answer: 1. It is highly likely that the risk of developing contrast‐induced nephropathy (CIN) after coronary angiography (CAG) increases in chronic kidney disease (CKD) patients, as the risk increases as kidney function decreases
In a study investigating the association between CIN and cardiovascular events in 9512 patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), CIN occurred in 12.7% of patients and the incidence of cardiovascular events was significantly higher in CIN-onset patients than in the patients who did not develop CIN 1 year after PCI (22.0 vs. 15.4%, p < 0.0001)
Summary
Diagnostic imaging using iodinated contrast media is an essential procedure in the clinical setting and provides a large amount of beneficial information. This book, which was published in Tokyo Igakusya, was approved by JSN, JRS and JCS Science Advisory and Coordinating Committee in 2018 This is the English version of that Japanese book. The Japan Radiological Society (JRS), the Japanese Circulation Society (JCS), and the Japanese Society of Nephrology (JSN) collaborated and published a guideline on the use of iodinated contrast media in patients with kidney disease (CIN guideline 2012). In our revised CIN guideline, we changed the clinical question (CQ) on the diagnosis of CIN to “How should CIN be diagnosed?” and followed the diagnostic criteria of the previous guideline (“CIN is defined as an increase in serum creatinine (SCr) levels by ≥ 0.5 mg/dL or ≥ 25% from baseline within 72 h after a contrast radiography using iodinated contrast media.”), but decided to include KDIGO’s AKI diagnostic criteria. Since the ESUR guideline 2018 was available after the last meeting of the committee on February 18, 2017, the committee reconfirmed their consistency with the revision of this guideline
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
